ABSTRACT Bolus i.v. injections of 1.2 N HCl elicit a rapid but transient pulmonary vasoconstriction in broiler chickens. In mammals, the pulmonary vasoconstrictive response to bolus acid injection depends on increased synthesis of thromboxane A 2 ; however, the vascular responsiveness of domestic fowl to thromboxane previously had not been evaluated. In the present study, we tested the hypothesis that, if HCl triggers pulmonary vasoconstriction by stimulating thromboxane A 2 synthesis in broilers, then bolus i.v. injections of the potent thromboxane A 2 mimetic U44069 (9,11-dideoxy-9a,11a-epoxy-methanoprostaglandin F 2a ; 1 mmol/mL; 0.5 mL injected volume) should trigger hemodynamic responses similar to those elicited by HCl (1.2 N; 1.5 mL injected volume). Both HCl and the thromboxane mimetic elicited twofold or greater increases in pulmonary vascular resistance, which in turn increased pulmonary arterial pressure by 50% despite concurrent reductions in cardiac output. The reductions in cardiac output were associated with reductions in stroke volume but not heart rate. The thromboxane mimetic also increased the total peripheral resistance, which minimized the reduction in mean systemic arterial pressure associated with the decrease in cardiac output. In contrast, HCl injections did not increase total peripheral resistance; consequently, the reduction in cardiac output caused the mean systemic arterial pressure to decrease by 30 mm Hg. Mannitol (2.5%; 1.5 mL) was injected i.v. as a volume control, and had no influence on any of the variables. This study provides the first direct evidence that thromboxane is a potent pulmonary vasoconstrictor in broilers, and provides support for the hypothesis that thromboxane mediates the pulmonary vasoconstrictive response to bolus i.v. injections of HCl. The differential response of the systemic vasculature to the thromboxane mimetic and HCl may indicate that cardiopulmonary responses to HCl injections are not mediated solely via thromboxane production. Alternatively, a direct dilatory effect of elevated hydrogen ion concentrations on the systemic vasculature may have counteracted any tendency for simultaneously evolved endogenous thromboxane to elicit systemic vasoconstriction.
INTRODUCTION
The pathophysiological progression leading to pulmonary hypertension syndrome (PHS, ascites) in broilers can be initiated or aggravated by a variety of conditions that increase pulmonary vascular resistance or attenuate flow-dependent pulmonary vasodilation (Wideman and Bottje, 1993; Kirby, 1995a,b, 1996; Wideman et al., 1996a Wideman et al., ,b, 1997 Wideman et al., , 1998a . In mammals, metabolic acidosis tends to modestly increase pulmonary vascular resistance, whereas alkalosis profoundly reduces pulmonary vascular resistance, particularly under hypoxic conditions (Redding et al., 1988; Farrukh et al., 1989; Yamaguchi et al., 1989; Brimioulle et al., 1990; Marshall and Marshall, 1992) . Similar influences of acid-base balance on pulmonary vascular resistance were inferred when broiler chickens were fed acidified or alkalinized diets during exposure to hypobaric hypoxia, or when metabolic acidosis was initiated by infusing HCl intravenously (Owen et al., 1994; Wideman et al., 1998b) . Mammals and broilers respond with a more profound pulmonary vasoconstriction when acid loading is accomplished by rapid i.v. bolus injection than when an equivalent acid load is infused gradually, even when equivalent changes in arterial blood pH are attained. The available evidence indicates rapid bolus injections of acid trigger pulmonary vasoconstriction by stimulating blood cells, platelets or thrombocytes, and vascular tissues to release vasoactive 2 Sigma-Aldrich, St. Louis, Transonic Systems Inc., Ithaca, NY 14850. 4 Dow Corning Corp., Midland, MI 48686-0994. 5 World Precision Instruments, Sarasota, FL 34230. 6 Biopac Systems, Inc., Goleta, CA 93117.
compounds (Lloyd, 1966; Barer et al., 1967; Hyman et al., 1971; Orr et al., 1987 Orr et al., , 1990 Shirer et al., 1988; Marshall and Marshall, 1992; Wideman et al., 1998b) .
In mammals, several chemical messengers elicit pulmonary vasoconstriction through stimulation of thromboxane synthesis by blood platelets or lung tissues (Hyman et al., 1978; Rabinovitch et al., 1988; Faltin et al., 1996) , and alkalosis reduces thromboxane-induced and hypoxia-induced pulmonary vasoconstriction (Redding et al., 1988) . The transient cardiopulmonary response to bolus HCl infusion in cats is caused by thromboxane A 2 synthesized in the blood (Orr et al., 1990) . Thromboxane A 2 itself is highly labile and has an extremely short biologic half-life (Hyman et al., 1978; Coleman et al., 1981) ; consequently, two relatively stable thromboxane A 2 mimetics, U46619 (9,11-dideoxy-11a,9a-epoxymethanoprostaglandin F 2a FW 350.5) and U44069 (9,11-dideoxy-9a,11a-epoxy-methanoprostaglandin F 2a ; FW 350.5), typically are used to elicit pulmonary vasoconstriction in mammals (Kadowitz et al., 1975; Rose et al., 1976; Tyler et al., 1978; Coleman et al., 1981; Lundergan et al., 1988; Redding et al., 1988; Orr et al., 1993) . In the present study, U44069 was injected i.v. to evaluate the pulmonary and systemic hemodynamic responses of clinically healthy broilers to thromboxane. The hemodynamic responses to i.v. injections of HCl also were evaluated in the same birds. We tested the hypothesis that HCl and U44069 should elicit similar hemodynamic responses if bolus i.v. injections of HCl trigger pulmonary vasoconstriction by stimulating thromboxane A 2 synthesis in broilers.
MATERIALS AND METHODS
Male broiler chicks were reared on fresh wood shavings litter in an environmental chamber (8 m 2 floor space). They were brooded at 32 and 30 C during Weeks 1 and 2, respectively, and thereafter the temperature was maintained at 24 C. Chicks were fed a corn-soybean meal broiler ration formulated to meet or exceed the minimum NRC (1984) standards for all ingredients. Feed and water were provided for ad libitum consumption.
Initial studies were conducted during November of 1996 to identify the bolus i.v. dose of thromboxane mimetic U44069 2 required to consistently elevate pulmonary arterial pressure. Three male broilers, 38-to 40-d-old, were anesthetized to a light surgical plane with intramuscular injections of allobarbital (5,5-diallylbarbituric acid 2 25 mg kg/BW). Cannulae were inserted in a pulmonary artery and an anterior tibial vein (Wideman et al., 1998b) . The U44069 was diluted to 950 nmol/mL in 2.5% mannitol (25 g mannitol/L of water), and injected i.v. via the anterior tibial vein cannula in bolus doses of 95 to 950 nmol. Injections of U44069 within the 300 to 500 nmol range triggered acute but transient pulmonary hypertension. Subsequent experiments were conducted on eight fully instrumented broilers, 46 to 48 d of age, during October of 1997. The surgical protocol has been described previously (Wideman and Kirby, 1995b; Wideman et al., 1996a Wideman et al., ,b, 1998a . Clinically healthy males (2,803 ± 83 g body mass; mean ± SEM) were anesthetized to a surgical plane (5,5-diallylbarbituric acid; 25 mg kg/BW), fastened in dorsal recumbency, and the thoracic inlet was opened. A Transonic ultrasonic flowprobe 3 was positioned on the left pulmonary artery, the probe was connected to a Transonic T206 blood flow meter 3 to confirm signal acquisition, then the skin of the thoracic inlet was sealed with surgical wound clips. Silastic ® Tubing 4 filled with heparinized saline was inserted through the left cutaneous ulnar vein and was advanced into the right pulmonary artery as judged by pressure tracings (Guthrie et al., 1987; Owen et al., 1995) . The distal end of the cannula was attached to a BLPR blood pressure transducer 5 interfaced through a Transbridge ™ preamplifier 5 to a Biopac MP 100 data acquisition system using AcqKnowledge software. 6 The left brachial artery and the right cutaneous ulnar vein were cannulated with polyethylene tubing filled with heparinized saline. The arterial cannula was advanced to a position near the descending aorta, and was attached to a blood pressure transducer for continuous monitoring of systemic arterial pressure.
Throughout each experiment, 2.5% mannitol was infused through the venous cannula at a constant rate (0.1 mL/min·kg BW) to hydrate the birds and serve as a vehicle for administering acid or thromboxane mimetic. When surgical preparations were complete and a stabilization period of 20 min had elapsed, control data were collected for 5 min, and a 1.5-mL bolus of 2.5% mannitol was injected i.v. as a vehicle and volume control. Thereafter, bolus injections of 1.2 N HCl in 2.5% mannitol (1.5 mL injected volume), or 1 mmol/mL) thromboxane mimetic U44069 (0.5 mL injected volume, 500 nmol injected dose), were administered at 10-min intervals in random order to provide duplicate evaluations of each substance per bird. The U44069 was stored at -20 C until immediately prior to injection, when it was thawed and diluted to 1 mmol/mL with 2.5% mannitol. The 1.5 mL injected volume of 1.2 N HCl in 2.5% mannitol previously was a low volume that consistently triggered pulmonary hypertension in broilers (Wideman et al., 1998b) . At the end of the experiments, birds were killed with 10 mL i.v. of 0.1 M KCl. Necropsies were not conducted.
The Biopac MP 100 data acquisition system recorded three primary data channels, including systemic arterial pressure in millimeters Hg, pulmonary arterial pressure (millimeters Hg), and blood flow through the left pulmonary artery (milliliters per minute). Heart rate (beats per minute) was obtained by counting systolic peaks over time in the pulmonary arterial pressure recording. Average values for these parameters were measured electronically 5 min into the initial control period (Sample Interval A), coincident with the maximum pulmonary arterial pressure recorded during the 5 min following the mannitol bolus injection (Sample Interval B), immediately preceding each injection of HCl or thromboxane mimetic (Preinjection Baseline: Sample Intervals C, E, G, I), during the maximum increase in pulmonary arterial pressure attained within the first 5 min after each HCl or thromboxane mimetic bolus injection (Peak values: Sample Intervals D, F, H, J), and 10 min after the final injection (Final baseline: Sample Interval K).
The protocol used for data averaging previously was demonstrated to accurately compensate for the influences of pulse pressure and respiration on pulmonary and systemic arterial pressures (Wideman et al., 1996a,b) . The resulting primary values for systemic arterial pressure, pulmonary arterial pressure, blood flow through the left pulmonary artery, and heart rate were used to calculate cardiac output, stroke volume, pulmonary vascular resistance, and total peripheral resistance. Based on the assumption that cardiac output (milliliters per minute) normally is divided approximately equally between two lungs of equal size, cardiac output was calculated as 2 × blood flow. The cardiac output is the product of heart rate × stroke volume (milliliters per beat), consequently stroke volume was calculated as cardiac output/heart rate. Assuming the pressure gradients across the pulmonary and systemic circulations are essentially equal to pulmonary arterial pressure and systemic arterial pressure, respectively (Wideman et al., 1996a (Wideman et al., ,b, 1998a , then the relationships between pressure gradients, flow rates, and resistances are summarized by the respective equations: pulmonary arterial pressure = cardiac output × pulmonary vascular resistance, and mean systemic arterial pressure = cardiac output × total peripheral resistance. Thus, pulmonary vascular resistance was calculated in relative resistance units as pulmonary arterial pressure (millimeters of Hg)/cardiac output (milliliters per minute), and total peripheral resistance was calculated in resistance units as mean systemic arterial pressure (millimeters Hg)/ cardiac output (Besch and Kadono, 1978; Sturkie, 1986; Wideman et al., 1996a Wideman et al., ,b, 1998a .
Data were analyzed using the Sigma Stat ® Repeated Measures Analysis of Variance procedure, and means were differentiated by the Student-Newman-Keuls method (Jandel Scientific, 1994) . Peak responses to bolus injections were considered significant when they differed (P ≤ 0.05) from the preinjection baseline value immediately preceding each injection.
RESULTS
Typical hemodynamic responses of individual broilers to i.v. injections of the thromboxane mimetic U44069
and HCl are shown in Figure 1 . Both the thromboxane mimetic and HCl triggered increases in pulmonary arterial pressure accompanied by decreases in mean systemic arterial pressure and cardiac output. These variables returned to preinjection baseline values within approximately 300 s postinjection. Individual birds differed in the time required to attain the peak pulmonary arterial pressure responses following injection of the thromboxane mimetic or HCl, and it consistently took longer (P < 0.05) to attain the peak pulmonary arterial pressure response after both injections of HCl (81.5 ± 7.9 and 82.8 ± 8.6 s, mean ± SEM, for HCl 1 and 2, respectively) than after both injections of the thromboxane mimetic (26.3 ± 4.5 and 21.1 ± 2.8 s, mean ± SEM, for thromboxane mimetic 1 and 2, respectively). It is these peak pulmonary hypertensive FIGURE 2. Pulmonary arterial pressure and pulmonary vascular resistance (mean ± SEM, n = 8) during the initial 20 min control period (sample interval A), coincident with the maximum pulmonary arterial pressure recorded during the 5 min following an injection of 2.5% mannitol (volume control: sample interval B), immediately preceding each injection of HCl or thromboxane (pre-Injection baseline: sample intervals C, E, G, I), during the maximum increase in pulmonary arterial pressure attained within the first 5 min after duplicate HCl and thromboxane bolus injections (peak values: sample intervals D, F, H, J), and 10 min after the final injection (sample interval K). Asterisks designate significant increases (P ≤ 0.05) compared with the preinjection baseline. FIGURE 3. Cardiac output, stroke volume, and heart rate (mean ± SEM, n = 8) during the initial 20 min control period (sample interval A), coincident with the maximum pulmonary arterial pressure recorded during the 5 min following an injection of 2.5% mannitol (volume control: sample interval B), immediately preceding each injection of HCl or thromboxane (preinjection baseline: sample intervals C, E, G, I), during the maximum increase in pulmonary arterial pressure attained within the first 5 min after duplicate HCl and thromboxane bolus injections (peak values: sample intervals D, F, H, J), and 10 min after the final injection (sample interval K). Asterisks designate significant decreases (P ≤ 0.05) compared with the preinjection baseline.
responses that were of primary interest; consequently, each peak in pulmonary arterial pressure was identified first, then contemporaneous data were extracted from the remaining physiograph channels for calculating the variables shown in Figures 2 to 4. The sequence for consecutive i.v. injections was randomized to minimize temporal or carryover interactions between HCl and thromboxane mimetic; however, for graphical representation in Figures 2 to 4 , the data are grouped in order of the first (HCl 1, Thromboxane 1) and then second (HCl 2, Thromboxane 2) injections of each substance.
Bolus mannitol injections had no influence on any of the hemodynamic variables (Figures 2 to 4) . The injections of HCl and thromboxane mimetic acutely increased pulmonary arterial pressure by an average of 50% above preinjection baseline values (Figure 2 ). These pulmonary hypertensive responses were associated with transient twofold or greater increases in pulmonary vascular resistance. The increase in pulmonary vascular resistance elicited by the second HCl injection was not lower in amplitude (P = 0.141) than the response to the first HCl injection (Figure 2) . The peak increases in pulmonary arterial pressure occurred while cardiac output was decreasing (Figure 3) . The reductions in cardiac output were associated with reductions in stroke volume but not heart rate after both injections of thromboxane mimetic. A tendency for the heart rate to increase (P = 0.062) after the first injection of HCl (HCl 1) partially attenuated the impact of a large reduction in stroke volume on the cardiac output. The highly variable heart rate following the second HCl injection contributed to the diminished probability (P = 0.07) that the reduction in cardiac output was caused by a reduced stroke volume (Figure 3) . The maximum reductions in cardiac output or stroke volume elicited by HCl and thromboxane mimetic injections did not differ (Sample Intervals D, F, H, J: P = 0.344 for cardiac output, P = 0.0967 for stroke volume). Baseline values for mean arterial pressure and total peripheral resistance declined from the beginning (Sample Interval A) to the end (Sample Interval K) of the experiment (Figure 4) . The FIGURE 4. Mean systemic arterial pressure and total peripheral resistance (mean ± SEM, n = 8) during the initial 20 min control period (sample interval A), coincident with the maximum pulmonary arterial pressure recorded during the 5 min following an injection of 2.5% mannitol (volume control: sample interval B), immediately preceding each injection of HCl or thromboxane (preinjection baseline: sample intervals C, E, G, I), during the maximum increase in pulmonary arterial pressure attained within the first 5 min after duplicate HCl and thromboxane bolus injections (peak values: sample intervals D, F, H, J), and 10 min after the final injection (sample interval K). Asterisks designate significant differences (P ≤ 0.05) compared with the preinjection baseline. Plus signs designate baseline values lower (P ≤ 0.05) than sample interval A. mean arterial pressure dropped below preinjection baseline values during the peak pulmonary hypertensive responses to all injections of HCl and thromboxane mimetic; however, both injections of HCl caused greater reductions in the mean arterial pressure than either injection of thromboxane mimetic (Sample Intervals D, F, H, J: P = 0.0352). The total peripheral resistance was not consistently affected by HCl injections, but increased in response to both injections of thromboxane mimetic.
DISCUSSION
In mammals, the pulmonary vasoconstrictive responses to bolus HCl injections are dependent on increased synthesis of thromboxane A 2 (Farrukh et al., 1989; Orr et al., 1990) , and in broilers bolus i.v. injections of HCl and the thromboxane mimetic U44069 induced rapid but transient increases in pulmonary vascular resistance and pulmonary arterial pressure. The peak pulmonary arterial pressure response to i.v. thromboxane mimetic injections required less than 30 s to develop, whereas the 80 s required for the peak response to HCl would be expected if blood cells, thrombocytes, or pulmonary tissues must first be provoked by the acid to synthesize endogenous thromboxane. The reductions in stroke volume and cardiac output after i.v. injections of the thromboxane mimetic and HCl resemble the responses previously observed when pulmonary vascular resistance was increased by tightening a snare around one pulmonary artery (Wideman et al., 1996a (Wideman et al., , 1998a , or by injecting epinephrine (Wideman, 1999) . In all of these experimental models, the maximal acute increment in pulmonary arterial pressure attainable by the right ventricle was inadequate to propel the normal cardiac output through an extensively elevated pulmonary vascular resistance; consequently, the impeded venous return to the left ventricle caused dependent reductions in stroke volume, cardiac output, and mean systemic arterial pressure. In mammals, i.v. infusion of the thromboxane mimetics U44069 and U46619 also elicit concurrent increases in pulmonary vascular resistance and pulmonary arterial pressure, and the concomitant reduction in stroke volume and cardiac output have been attributed to reduced left ventricular output rather than a reduction in myocardial contractility (Rose et al., 1976; Redding et al., 1988) .
The pulmonary hemodynamic responses observed in the present study are consistent with but do not prove a direct relationship between bolus acid injections and thromboxane release in broilers. Indeed, a key difference was evident in the systemic hemodynamic responses. The thromboxane mimetic triggered an overall systemic vasoconstriction, and it was this increase in total peripheral resistance that attenuated the contemporaneous reduction in mean systemic arterial pressure during the reduction in cardiac output. However, the first bolus HCl injection did not affect total peripheral resistance, and the second bolus injection tended to reduce total peripheral resistance (P = 0.07); consequently, large reductions in mean systemic arterial pressure occurred in direct proportion to the reductions in cardiac output. This key differential response of the systemic vasculature to the thromboxane mimetic and HCl may indicate the cardiopulmonary responses to bolus HCl injections are not mediated solely via thromboxane production. Alternatively, a direct dilatory effect of elevated hydrogen ion concentrations on the systemic vasculature may have counteracted any tendency for simultaneously evolved endogenous thromboxane to elicit systemic vasoconstriction. Previously, the total peripheral resistance decreased in response to the metabolic acidosis associated with constant HCl infusion, but was unaffected by bolus HCl injections (Wideman et al., 1998b) .
All factors contributing to an overall increase in the pulmonary vascular resistance theoretically can initiate or accelerate the pathophysiological progression leading to pulmonary hypertension syndrome in broilers (Wideman and Bottje, 1993; Wideman, 1997) . The present study provides the first direct evidence that thromboxane can trigger pulmonary vasoconstriction and pulmo-nary hypertension in domestic fowl. The functional significance of this observation relates to the presumed contribution of poor air quality to the onset of pulmonary hypertension syndrome. Accordingly, it has been proposed that inhaled dust and pathogens may cause focal damage to the gas exchange barrier and constriction of the pulmonary vasculature by increasing the intrapulmonary production of reactive oxygen species and thromboxane, coupled with reduced synthesis the vasodilator prostacyclin (Bottje and Wideman, 1995) . Indeed, various particulates and bacterial endotoxins stimulate endothelin-mediated thromboxanedependent increases in pulmonary vascular resistance and pulmonary arterial pressure in mammals (Morel et al., 1989; Longworth et al., 1994; Staub, 1994; Faltin et al., 1996) . Intrapulmonary cell-mediated processes also rapidly clear particulates from avian lungs (Brown et al., 1997; Fedde, 1998) . During endotoxin infusion in mammals, both the vasoconstrictor thromboxane and the vasodilator prostacyclin normally are produced, and can exert dynamically antagonistic influences on pulmonary vascular resistance depending on the experimental protocol (Longworth et al., 1994; Frank et al., 1996) . Similar mechanisms may be involved in the pathogenesis of ascites triggered in broilers by intratracheal inoculation with Escherichia coli and infectious bronchitis virus (Tottori et al., 1997) , or by pulmonary aspergillosis (Julian and Goryo, 1990) . The variable efficacy of aspirin on the incidence of ascites induced in broilers by cool temperatures and hypobaric hypoxia may reflect aspirin's nonspecific nullification of both the protective role of prostacyclin as well as the detrimental impact of thromboxane on pulmonary vascular resistance (Shlosberg et al., 1996; Balog et al., 1997) . Enhanced prostacyclin synthesis attenuates the pulmonary vasoconstriction induced by hypoxia or metabolic acidosis in mammals (Rabinovitch et al., 1988; Farrukh et al., 1989; Yamaguchi et al., 1989; Tod et al., 1992; Frank et al., 1996) . Cool temperatures and hypobaric hypoxia induce ascites by directly increasing the cardiac output and pulmonary vascular resistance without initiating a pulmonary inflammatory response per se (Wideman and Bottje, 1993; Wideman, 1997) ; consequently, aspirin may have little protective efficacy unless poor air quality or respiratory pathogens contribute substantially to the onset of pulmonary hypertension. Overall, inhibitors of thromboxane synthesis coupled with enhanced prostacyclin levels might be predicted to offer well-focused protection against inflammatory agents contributing to pulmonary hypertension syndrome in broilers. However, in human patients with primary pulmonary hypertension, effective pulmonary vasodilation transiently reduces pulmonary arterial pressure and increases cardiac output and blood oxygenation without consistently altering the rapid progression to death associated with pulmonary edema and congestive heart failure (Tod et al., 1992; Raffy et al., 1996) . Pharmacologic intervention with analogous specific modulators of pulmonary vascular resistance has not been evaluated as an approach for reducing ascites mortality in poultry.
